e-Therapeutics outlined its focused strategy in July, investing in a few select discovery programmes while it looks for partners. Business development activities are underway, as it raises awareness of its network-driven drug (NDD) discovery platform while advancing the immuno-oncology projects to a suitable stage for partnering. Given the proven capabilities of the company and growing interest in big data and artificial intelligence (AI) to enhance drug discovery, we expect e-Therapeutics to have fruitful discussions in the coming year. Our DCF valuation is unchanged at £53.8m or 20.4p/share.
26 Sep 2017
Executing the strategy
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Executing the strategy
e-Therapeutics plc (ETX:LON) | 9.3 0 0.3% | Mkt Cap: 54.3m
- Published:
26 Sep 2017 -
Author:
Mick Cooper PhD -
Pages:
3
e-Therapeutics outlined its focused strategy in July, investing in a few select discovery programmes while it looks for partners. Business development activities are underway, as it raises awareness of its network-driven drug (NDD) discovery platform while advancing the immuno-oncology projects to a suitable stage for partnering. Given the proven capabilities of the company and growing interest in big data and artificial intelligence (AI) to enhance drug discovery, we expect e-Therapeutics to have fruitful discussions in the coming year. Our DCF valuation is unchanged at £53.8m or 20.4p/share.